Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 306 participants.
Also called NCT01215097
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 306 participants
- Registry
-
NCT01215097
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China, Malaysia, Philippines
- Registry status
- Completed
Technical summary
Registry record NCT01215097. Randomized; double masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2012-04 (actual). Results posted on 2013-06-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Linagliptin
- Intervention (Drug)
- placebo
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01215097- Content hash
c2878e9e40166ff585b4c91b1afd82fa99e8f12b574a67e49448cc97f7a2a978